4-[5-chloro-1-(3,4-difluoro-benzoyl)-2-oxo-1,2-dihydro-pyridin-4-yloxy]-piperidine-1-carboxylic acid tert-butyl ester | 1356175-16-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[5-chloro-1-(3,4-difluoro-benzoyl)-2-oxo-1,2-dihydro-pyridin-4-yloxy]-piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 4-[5-chloro-1-(3,4-difluorobenzoyl)-2-oxopyridin-4-yl]oxypiperidine-1-carboxylate
• CAS: 1356175-16-0
• 化学式: C₂₂H₂₃ClF₂N₂O₅
• 分子量: 468.885
• InChiKey: ZHGWNLBTJRTBIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  76.2
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• [EN] SUBSTITUTED PYRIDINONE DERIVATIVES AND METHODS FOR MANUFACTURING THE SAME<br/>[FR] DÉRIVÉS DE PYRIDINONE SUBSTITUÉE ET LEURS PROCÉDÉS DE FABRICATION
  申请人：HYUNDAI PHARM CO LTD

  公开号：WO2012011707A2

  公开（公告）日：2012-01-26

  Disclosed are a novel compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and the compound-containing pharmaceutical composition for treating a metabolic disorder. Specifically, the disclosed compound is represented by [Formula 1]. The compound activates GPR119, and thus can be used for treating metabolic disorders, that is, diabetes mellitus, diabetes mellitus-related diseases, diabetes mellitus-related microvessel complications, diabetes mellitus-related large vessel complications, cardiovascular disorders, metabolic syndrome and its constituent diseases, obesity, and other diseases. In Formula 1, P1, P2, P3, P4, L1, R4, n4, X, Y, Z1 and Z2 are the same as defined above.